Merck Forecast, price target & analysts
Merck Target price 2025 - Analyst rating & recommendation
Merck Classifications & Recommendation:
Merck Price Target
| Target Price | €143.82 |
| Price | €115.70 |
| Potential | 24.30% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Merck 2026 . The average Merck target price is €143.82. This is 24.30% higher than the current stock price. The highest price target is €197.40 70.61% , the lowest is €101.00 12.71% . | |
| A rating was issued by 24 analysts: 17 Analysts recommend Merck to buy, 4 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 24.30% . Most analysts recommend the Merck stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
20 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €21.4b . This is 0.95% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €23.4b 10.23% , the lowest is €20.4b 3.68% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €21.2b | 0.78% |
|---|---|---|
| 2025 | €21.4b | 1.25% |
| 2026 | €22.0b | 2.69% |
| 2027 | €22.8b | 3.71% |
| 2028 | €23.9b | 4.91% |
| 2029 | €25.1b | 4.94% |
| 2030 | €26.0b | 3.49% |
| 2031 | €25.8b | 0.88% |
| 2032 | €26.5b | 2.71% |
19 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.1b . This is 6.69% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €7.2b 25.26% , the lowest is €5.6b 2.01% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €4.9b | 3.42% |
|---|---|---|
| 2025 | €6.1b | 24.60% |
| 2026 | €6.4b | 4.79% |
| 2027 | €6.8b | 4.88% |
| 2028 | €7.1b | 4.72% |
| 2029 | €7.5b | 6.58% |
| 2030 | €7.8b | 3.48% |
| 2031 | €8.0b | 1.99% |
| 2032 | €8.1b | 2.16% |
EBITDA Margin
| 2024 | 23.31% | 2.62% |
|---|---|---|
| 2025 | 28.68% | 23.05% |
| 2026 | 29.27% | 2.06% |
| 2027 | 29.60% | 1.13% |
| 2028 | 29.54% | 0.20% |
| 2029 | 30.00% | 1.56% |
| 2030 | 30.00% | 0.00% |
| 2031 | 30.87% | 2.90% |
| 2032 | 30.70% | 0.55% |
20 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.7b . This is 28.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €4.6b 59.51% , the lowest is €3.4b 19.85% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €2.8b | 1.66% |
|---|---|---|
| 2025 | €3.7b | 32.69% |
| 2026 | €3.8b | 3.96% |
| 2027 | €4.0b | 4.59% |
| 2028 | €4.5b | 12.88% |
| 2029 | €4.9b | 8.56% |
| 2030 | €5.1b | 3.69% |
| 2031 | €5.3b | 4.69% |
| 2032 | €5.4b | 2.04% |
Net Margin
| 2024 | 13.13% | 2.42% |
|---|---|---|
| 2025 | 17.20% | 31.03% |
| 2026 | 17.42% | 1.28% |
| 2027 | 17.56% | 0.80% |
| 2028 | 18.90% | 7.63% |
| 2029 | 19.55% | 3.44% |
| 2030 | 19.59% | 0.20% |
| 2031 | 20.69% | 5.62% |
| 2032 | 20.55% | 0.68% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
20 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €8.48 . This is 28.88% higher than earnings per share in the financial year 2024. The highest EPS forecast is €10.50 59.57% , the lowest is €7.89 19.91% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €6.39 | 1.69% |
|---|---|---|
| 2025 | €8.48 | 32.71% |
| 2026 | €8.81 | 3.89% |
| 2027 | €9.22 | 4.65% |
| 2028 | €10.40 | 12.80% |
| 2029 | €11.29 | 8.56% |
| 2030 | €11.71 | 3.72% |
| 2031 | €12.26 | 4.70% |
| 2032 | €12.51 | 2.04% |
P/E ratio
| Current | 17.12 | 29.52% |
|---|---|---|
| 2025 | 13.29 | 22.37% |
| 2026 | 12.79 | 3.76% |
| 2027 | 12.22 | 4.46% |
| 2028 | 10.83 | 11.37% |
| 2029 | 9.98 | 7.85% |
| 2030 | 9.62 | 3.61% |
| 2031 | 9.19 | 4.47% |
| 2032 | 9.01 | 1.96% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.59 and an P/S ratio of 2.23 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.62 | 25.36% |
|---|---|---|
| 2025 | 2.59 | 1.12% |
| 2026 | 2.52 | 2.62% |
| 2027 | 2.43 | 3.58% |
| 2028 | 2.32 | 4.68% |
| 2029 | 2.21 | 4.71% |
| 2030 | 2.13 | 3.37% |
| 2031 | 2.15 | 0.89% |
| 2032 | 2.10 | 2.64% |
P/S ratio
| Current | 2.25 | 28.73% |
|---|---|---|
| 2025 | 2.23 | 0.94% |
| 2026 | 2.17 | 2.62% |
| 2027 | 2.09 | 3.58% |
| 2028 | 1.99 | 4.68% |
| 2029 | 1.90 | 4.71% |
| 2030 | 1.83 | 3.37% |
| 2031 | 1.85 | 0.89% |
| 2032 | 1.80 | 2.64% |
Current Merck Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Aug 29 2025 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
| STIFEL EUROPE |
Buy
➜
Sell
|
Downgrade | Aug 15 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Aug 13 2025 |
| ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Aug 12 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Aug 29 2025 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Aug 29 2025 |
|
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Buy
|
Aug 25 2025 |
|
Downgrade
STIFEL EUROPE:
Buy
➜
Sell
|
Aug 15 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Aug 13 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Aug 12 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Aug 11 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
